Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perlegen Sciences has opened its portfolio of patented technologies that together enable whole genome association studies capable of assessing an individual's predisposition to specific disease risks and treatment outcomes.
Subscribe to our email newsletter
The family of six complementary patents covers methods of genetic analysis used to detect markers for multifactorial traits.
According to the company, these methods range from identification of tightly linked haplotype blocks and multi-loci markers to optimal matching of patient cases and controls, as well as methods for managing the massive data sets that accompany these analyses.
Bryan Walser, CEO of Perlegen, said: “The ability to determine which genetic markers are present in an individual across several areas of the genome – and combine them in order to help quantify risk of developing or showing a specific multifactorial trait – will be central to the field of genetic diagnostics going forward.”